SEPT9: A Specific Circulating Biomarker for Colorectal Cancer

Area of Science:

• Oncology
• Molecular Diagnostics
• Biomarker Discovery

Background:

• SEPT9 gene methylation is a well-established biomarker for colorectal cancer (CRC).
• The SEPT9 assay has been clinically utilized for over six years, demonstrating accuracy and reliability.
• Understanding the role of septin9 protein provides the theoretical basis for this diagnostic assay.

Purpose of the Study:

• To review the performance of the SEPT9 gene methylation assay for early CRC detection and screening.
• To analyze clinical trial data and compare SEPT9 assay performance with alternative methods.
• To discuss future applications of the SEPT9 assay in cancer management and prognosis.

Main Methods:

• Review of clinical trial data on SEPT9 gene methylation assay performance.
• Comparative analysis of SEPT9 assay against other CRC detection methods.
• Exploration of theoretical basis and development of the SEPT9 assay.

Main Results:

• SEPT9 gene methylation assay is proven to be accurate, reliable, fast, and convenient for CRC.
• Clinical data supports the efficacy of the SEPT9 assay in early CRC detection and screening.
• The assay shows potential for monitoring cancer recurrence and treatment effectiveness.

Conclusions:

• The SEPT9 gene methylation assay is a valuable tool for colorectal cancer diagnostics.
• Future applications include monitoring treatment response, predicting survival, and evaluating surgical outcomes.
• This chapter provides a comprehensive overview for researchers and clinicians on the SEPT9 assay.